Compare CKX & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | LEXX |
|---|---|---|
| Founded | 1930 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 18.9M |
| IPO Year | 1998 | N/A |
| Metric | CKX | LEXX |
|---|---|---|
| Price | $11.13 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 7.6K | ★ 307.9K |
| Earning Date | 02-22-2026 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.14 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $897,333.00 | $522,000.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | N/A | $78.83 |
| P/E Ratio | $48.82 | ★ N/A |
| Revenue Growth | N/A | ★ 5.05 |
| 52 Week Low | $8.66 | $0.46 |
| 52 Week High | $13.25 | $1.91 |
| Indicator | CKX | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 75.55 | 47.56 |
| Support Level | $8.98 | $0.68 |
| Resistance Level | $10.81 | $0.86 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | 0.27 | 0.02 |
| Stochastic Oscillator | 100.00 | 50.80 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. CKX has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Surface segment. Geographically, it generates all of its revenue from the United States of America.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.